Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 September 2025 | Story Reuben Maeko | Photo Sizwe Gwiba
Dermatology Unit
Celebrating the milestone launch of the Dermatologic Surgery Unit at Universitas Academic Hospital, a new chapter for advanced patient care, training, and research.

The Department of Dermatology in the Faculty of Health Sciences at the University of the Free State (UFS) marked a historic milestone with the official opening of the Dermatologic Surgery Unit at Universitas Academic Hospital on 11 September 2025. This new facility represents a significant step forward in expanding access to specialised surgical treatment for complex dermatological conditions, while simultaneously strengthening academic training and research opportunities for registrars and medical students.

The inauguration was attended by Prof Francois P Retief, a distinguished medical pioneer from the UFS Faculty of Health Sciences, after whom one of the faculty buildings is named. His wife, Ria Retief, extended words of gratitude and gifted a book from his medical library to Prof Frans Maruma, Head of the Department of Dermatology.

“We are truly honoured to be included in this significant milestone and to witness the beginning of what we know will be an impactful journey aimed at improving patient care,” Ria Retief said. “It is a privilege to celebrate this remarkable achievement with you, and we deeply admire your dedication and vision.”

 

Honouring a legacy in dermatology

In his opening address, Prof Maruma reflected on the journey that led to the establishment of the Dermatologic Surgery Unit, acknowledging the teamwork, persistence, and collaboration that made the vision a reality.

“The Derm-Surgery Unit is not just a surgical space – it is a testament to teamwork, perseverance, and the drive to advance patient-centred care in dermatology,” he said. “We pay homage to visionary leadership that has afforded us the opportunity to expand dermatology services to include surgery and as a skill sacrosanct to modern practice. This is not only about healing, but also about preparing our registrars for the realities of clinical practice through work-integrated learning.”

Prof Maruma extended appreciation to colleagues and staff members in the Department of Dermatology, as well as strategic partners in the UFS, the Department of Health, the pharmaceutical industry, and private practitioners who dedicate their time to teaching and mentoring. Special acknowledgement was given to Dr Marc Roscher, Dr Harriet Makuru, and Dr Yashica Khalawan, who played a pivotal role in supporting the project’s launch.

The programme also included remarks by senior academic leaders. Prof Alicia Sherriff, Acting Head of the School of Clinical Medicine, commended the department for its innovation and foresight in the face of resource limitations, highlighting the potential for further expansion through collaboration with both public and private stakeholders.

While cutting the ribbon, Prof Thabiso Mofokeng, Head of Internal Medicine at Universitas Academic Hospital, emphasised that the launch of the Derm-Surgery Unit reflects the broader ethos of the clinical platform: to enable world-class training, foster research excellence, and deliver quality healthcare that is responsive to the needs of the community.

The launch underscored the university’s commitment to Work-Integrated Learning (WIL), bridging the gap between academic training and real-world clinical demands. The Derm-Surgery initiative is designed to equip registrars with essential industry-specific skills in procedural dermatology while fostering collaboration between private and public healthcare sectors. The evening concluded with awards recognising individuals whose contributions ensured the success of this landmark opening.

Looking ahead, the Department of Dermatology envisions its Derm-Surgery Unit as more than just a clinical unit – it is set to become a hub of advanced patient care, high-impact training, and cutting-edge research. This initiative strengthens the UFS Faculty of Health Sciences’ role as a leader in medical education and healthcare innovation in the Free State and beyond.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept